EKSO
Ekso Bionics Holdings, Inc.NASDAQHealthcare$9.40+3.72%ClosedMarket Cap: $22.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.62
P/S
1.85
EV/EBITDA
-2.39
DCF Value
$-84.49
FCF Yield
-49.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.5%
Operating Margin
-104.1%
Net Margin
-91.4%
ROE
-110.5%
ROA
-58.2%
ROIC
-101.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.1M | 53.2% | $-4.5M | $-4.7M | $-1.57 | — |
| FY 2025 | $12.8M | 53.5% | $-13.3M | $-11.7M | $-4.91 | — |
| Q3 2025 | $4.2M | 60.3% | $-1.4M | $-1.4M | $-0.54 | — |
| Q2 2025 | $2.1M | 39.8% | $-4.0M | $-2.7M | $-1.24 | — |
| Q1 2025 | $3.4M | 53.5% | $-3.4M | $-2.9M | $-0.11 | — |
| Q4 2024 | $5.1M | 53.3% | $-2.2M | $-3.4M | $-0.14 | — |
| FY 2024 | $17.9M | 53.1% | $-10.5M | $-11.3M | $-0.56 | — |
| Q3 2024 | $4.1M | 53.5% | $-2.6M | $-2.1M | $-0.10 | — |
| Q2 2024 | $5.0M | 53.3% | $-2.3M | $-2.4M | $-0.13 | — |
| Q1 2024 | $3.8M | 51.9% | $-3.3M | $-3.4M | $-0.20 | — |
| Q4 2023 | $4.8M | 48.9% | $-3.4M | $-3.2M | $-0.22 | — |
| FY 2023 | $18.3M | 49.7% | $-15.1M | $-15.2M | $-1.10 | — |